PharmaMar

PHM · BME

Public Market Listing

PHMBME

BME primary exchange listing

Live quotes, historical charts, and market capitalization for PharmaMar are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
Alkylating DrugSmall molecule
Small Cell Lung Cancer
Phase 3
eEF1A2 (eukaryotic translation elongation factor 1-alpha 2)Small molecule
Multiple Myeloma

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
LurbinectedinPhase 3Relapsed Small Cell Lung Cancer
Est. primary completion 2027-12-31 · NCT06496048 · CT.gov ↗
What to watch
2028 (1)
January 2028 (1)
LurbinectedinPhase 1/2Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
Est. primary completion 2028-01-28 · NCT05734066 · CT.gov ↗
What to watch
2029 (2)
August 2029 (2)
LurbinectedinPhase 2Extensive-stage Small-cell Lung Cancer
Est. primary completion 2029-08-04 · NCT07459634 · CT.gov ↗
What to watch
LurbinectedinPhase 3Leiomyosarcoma
Est. primary completion 2029-08-30 · NCT06088290 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 September 2026WithdrawalLurbinectedin (Zepzelca)FDA approves voluntary withdrawal of the Zepzelca second-line SCLC accelerated approval indication
US, FDA · Jazz Pharmaceuticals Ireland, Ltd. · Source ↗
June 2026Topline resultLurbinectedinPhase 3 LAGOON did not meet its overall survival primary endpoint
7 October 2025FDA action dateLurbinectedinPDUFA date set for Zepzelca plus atezolizumab
US, FDA · Source ↗
2 October 2025ApprovalLurbinectedinFDA approves Zepzelca plus atezolizumab as first-line maintenance for ES-SCLC
US, FDA · Source ↗
10 June 2025Filing acceptedLurbinectedinFDA accepts sNDA for Zepzelca plus atezolizumab
US, FDA · Source ↗
10 June 2025Priority reviewLurbinectedinFDA grants Priority Review to Zepzelca plus atezolizumab sNDA
US, FDA · Source ↗

Financial reports

No financial reports recorded.